Shanghai Kaibao Pharmaceutical Co Ltd

Shanghai Kaibao Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 13.41, indicating a significant buffer of current assets over current liabilities. The company's price-to-book ratio is 1.35, and its price-to-tangible-book ratio is also 1.35, suggesting that the market values the company's equity at a moderate premium to its book value. The company's market capitalization is 5.97 billion CNY, with a price-to-earnings ratio of 21.44, which is in line with typical valuation metrics for the pharmaceutical industry. In terms of profitability, the company's return on equity is 6.31%, and its return on assets is 5.83%, both of which are below the typical industry benchmarks for pharmaceutical firms. The company's operating income of 324.95 million CNY and net income of 278.58 million CNY reflect a healthy but not exceptional performance relative to its revenue of 1.15 billion CNY. The gross profit margin of 80.7% is strong, indicating efficient cost management in production and sourcing. The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed in the available data. The company operates a single business segment, which is typical for many pharmaceutical firms in the early stages of diversification. The lack of geographic diversification may expose the company to regulatory and economic risks specific to the Chinese market. Looking ahead, the company's growth trajectory is expected to remain stable, with no significant changes in revenue or earnings projected for the next fiscal year. The company's capital expenditure of -27.04 million CNY indicates a reduction in investment in physical assets, which may be a strategic decision to preserve cash or a sign of reduced expansion plans. The company's free cash flow of 149.95 million CNY provides flexibility for dividends, debt repayment, or strategic investments. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.0, indicating no leverage, which is a conservative capital structure but may also suggest a lack of financial leverage to drive growth. The company's net cash position is negative after subtracting total debt, which could be a concern if not managed carefully. The company's risk assessment does not indicate any significant regulatory or operational risks at this time. Recent events and filings do not show any material changes in the company's operations or financial position. The company's financial statements and disclosures are consistent with its historical performance, and there are no indications of material non-disclosure or accounting irregularities. The company's recent capital structure and liquidity position remain stable, with no significant changes in shares outstanding or market price.